Published • loading... • Updated
AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada
- AMO Pharma agreed with regulatory agencies in the U.S., U.K., and Canada on the design of a clinical study for AMO-02 to treat congenital myotonic dystrophy type 1 .
- The U.S. FDA, U.K. MHRA, and Health Canada provided advice on the study's design and primary outcome in meetings over the past six months.
- The study will assess hospitalization as the primary outcome and include multiple functional assessments as secondary outcomes, following regulatory feedback.
- AMO Pharma expects to provide an update on the study's initiation in the third quarter of 2026.
Insights by Ground AI
37 Articles
37 Articles
The Times of Northwest Indiana+36 Reposted by 36 other sources
AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada
Based on regulatory agency feedback, the Company plans a registrational study that will evaluate hospitalization as the primary outcome measure, supported by multiple functional assessments as secondary outcome measures.
·Cherokee County, United States
Read Full ArticleCoverage Details
Total News Sources37
Leaning Left6Leaning Right4Center21Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 19%
C 68%
13%
Factuality
To view factuality data please Upgrade to Premium
